Published Oct. 6, 2026. The United Kingdom has accepted all 44 recommendations from an independent commission on artificial intelligence in healthcare, setting out a shift toward continuous monitoring of medical AI rather than relying only on approval at a single point in time.
The government announced the decision on Oct. 6 in an official response led by the Medicines and Healthcare products Regulatory Agency. It also opened applications for the third phase of AI Airlock, the MHRA’s regulatory sandbox for AI-enabled medical devices.
What the new approach changes
The commission’s framework calls for regulation across the full lifecycle of an AI product. That means authorities would examine how a tool performs after deployment and as software, data and clinical use change, instead of treating a premarket assessment as the final safety check.
The response also emphasizes transparency for patients, including information about when AI is being used in their care; stronger public and patient participation; clearer accountability; and routes for redress when something goes wrong. These are policy commitments and a regulatory roadmap, not an approval of any individual AI medical product.
AI Airlock enters a third phase
AI Airlock allows developers and regulators to test difficult questions around AI-enabled medical devices in a controlled program. The new phase will focus on themes drawn from the commission’s recommendations, including real-world monitoring after a product enters use.
Applications are open now, with the first group of participating innovators expected to be selected in November 2026. The government said a new program board will coordinate work across the MHRA, NHS partners, devolved governments and other agencies.
Implementation will extend into 2027
The announcement begins the implementation process rather than completing it. A full roadmap is due by spring 2027, and Scotland said it will set out its own response in due course while continuing to work with UK partners on shared issues.
The commission published its recommendations on Sept. 10 after a year-long evidence-gathering process involving more than 12,000 patients, clinicians and members of the public. The government’s full policy response details the initial delivery priorities and next steps.
Why it matters
Medical AI can assist with diagnosis, workflow and treatment decisions, but performance can shift as patient populations, clinical practices and software models change. Lifecycle monitoring is intended to catch those changes while giving developers clearer rules for bringing useful products to patients.
AskNovus will track how the commitments become enforceable rules. See more in Artificial Intelligence, Health News and Science News.
Featured image: Photo by Accuray on Unsplash.